source
- Novartis says it will keep seeking sub-$2 billion bolt-on deals worldwide, staying geography-agnosticNovartis CEO Vas Narasimhan told investors on the second‑quarter earnings call that the company will continue to pursue bolt‑on acquisitions below $2 billion and has no plans to overhaul its busine…
- Agios halts sickle cell drug program after disappointing phase 2 resultsAgios announced it is stopping development of its next‑generation pyruvate kinase activator, tebapivat, for sickle cell disease after a phase 2 trial failed to meet expectations. The study enrolle…